CNSP Stock Price, CNS Pharmaceuticals Inc Quote, Chart

Market Summary

USD0.220.00

Delayed

0.00%

CNSP Stock Price

View Fullscreen

CNSP RSI Chart

CNSP Valuation

Market Cap

2.6M

Price/Earnings (Trailing)

-0.15

Price/Sales (Trailing)

75.76

Price/Free Cashflow

-0.21

CNSP Price/Sales (Trailing)

CNSP Profitability

Return on Equity

394.18%

Return on Assets

-1.1K%

Free Cashflow Yield

-479.84%

CNSP Fundamentals

CNSP Revenue

Revenue (TTM)

34.4K

Rev. Growth (Qtr)

-3.87%

CNSP Earnings

Earnings (TTM)

-17.5M

Earnings Growth (Yr)

28.13%

Earnings Growth (Qtr)

34.05%

Breaking Down CNSP Revenue

Last 7 days

10%

Last 30 days

10%

Last 90 days

-21.4%

Trailing 12 Months

-83.7%

How does CNSP drawdown profile look like?

CNSP Financial Health

Current Ratio

0.26

CNSP Investor Care

Shares Dilution (1Y)

186.05%

Diluted EPS (TTM)

-3.15

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q4
2024	34.4K	0
2023	0	27.7K
2022	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of CNS Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 01, 2024	gumulka jerzy	bought	9,999	0.3	33,333	-
Feb 01, 2024	evans carl anthony	bought	9,999	0.3	33,333	-
Feb 01, 2024	downs christopher	bought	19,999	0.3	66,666	chief financial officer
Feb 01, 2024	climaco john m	bought	49,999	0.3	166,666	chief executive officer
Aug 22, 2023	downs christopher	bought	34,176	1.2658	27,000	chief financial officer
Aug 16, 2023	climaco john m	bought	4,944	1.798	2,750	chief executive officer
Apr 28, 2023	downs christopher	acquired	-	-	521	chief financial officer
Apr 28, 2023	climaco john m	acquired	-	-	1,250	chief executive officer
Apr 19, 2023	gumulka jerzy	bought	4,250	1.7	2,500	-
Apr 17, 2023	downs christopher	bought	9,920	3.2	3,100	chief financial officer

Which funds bought or sold CNSP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	new	-	9,914	9,914	-%
May 15, 2024	STATE STREET CORP	unchanged	-	-20,256	8,165	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	-61.00	24.00	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	77,800	281	282	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	added	286	15,562	170,502	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	70.36	-2,597	2,451	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	7,894	7,894	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	32,954	32,954	-%
May 14, 2024	FSM Wealth Advisors, LLC	unchanged	-	-17,329	6,908	-%
May 13, 2024	XTX Topco Ltd	added	87.25	-5,823	6,780	-%

Are Funds Buying or Selling CNSP?

Are funds buying CNSP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CNSP

No. of Funds

Unveiling CNS Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.99%	676,203	SC 13G/A
Aug 01, 2023	priebe waldemar	0.3%	0	SC 13G
Feb 14, 2023	armistice capital, llc	9.99%	165,456	SC 13G

Recent SEC filings of CNS Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	8-K	Current Report
May 15, 2024	10-Q	Quarterly Report
May 09, 2024	S-3	S-3
May 07, 2024	8-K	Current Report
May 03, 2024	8-K	Current Report
Apr 15, 2024	8-K	Current Report
Apr 10, 2024	4	Insider Trading
Apr 10, 2024	4	Insider Trading
Apr 10, 2024	4	Insider Trading
Apr 10, 2024	4	Insider Trading

Peers (Alternatives to CNS Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

CNS Pharmaceuticals Inc News

Latest updates

CNS Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)						(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4
Revenue	-3.9%	7.00	7.00	13.00	8.00	-	-
Operating Expenses	-34.1%	3,545	5,379	4,534	4,025	4,927	5,135
S&GA Expenses	-100.0%	-	1,108	1,123	1,180	1,359	2,153
R&D Expenses	-43.1%	2,430	4,272	3,411	2,846	3,568	2,982
Interest Expenses	130.0%	7.00	3.00	2.00	4.00	5.00	2.00
Income Taxes	-	-	-	-	-	-	-
Net Income	34.1%	-3,544	-5,375	-4,522	-4,021	-4,931	-5,136
Net Income Margin	25.5%	-507.41*	-680.87*	-	-	-	-
Free Cashflow	-25.8%	-3,194	-2,538	-3,378	-3,402	-4,824	-2,305

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Assets	-2.4%	1,661	1,701	2,328	6,452	7,415	13,053	9,638	12,447	15,872	8,757	11,507	14,239	13,145	15,853	2,985	3,986	6,211	7,912	1,398	683
Current Assets	0.6%	1,601	1,591	2,062	6,071	6,972	12,565	8,700	11,397	14,733	7,477	11,156	13,883	12,786	15,496	2,516	3,954	6,189	7,894	1,390	588
Cash Equivalents	48.6%	815	549	910	4,279	5,111	10,055	7,027	8,959	12,440	5,005	8,326	6,886	11,075	14,039	1,307	2,626	5,380	7,241	630	555
Net PPE	-12.7%	4.00	5.00	3.00	3.00	4.00	6.00	9.00	11.00	13.00	16.00	18.00	21.00	24.00	23.00	28.00	31.00	23.00	18.00	8.00	-
Liabilities	-0.7%	6,091	6,133	4,069	3,997	3,923	4,920	1,244	924	1,069	2,594	2,407	1,831	1,902	1,905	511	261	336	311	1,398	1,233
Current Liabilities	-0.7%	6,091	6,133	4,069	3,997	3,923	4,920	1,244	924	1,069	2,594	2,407	1,831	1,902	1,905	511	261	336	311	1,398	1,233
Shareholder's Equity	0.0%	-4,430	-4,432	-	2,454	3,492	8,133	7,568	10,697	13,977	6,163	9,100	12,408	11,243	13,948	2,474	3,725	5,875	7,601	-	-
Retained Earnings	-5.1%	-73,111	-69,566	-64,191	-59,668	-55,647	-50,715	-44,752	-41,333	-37,767	-35,441	-32,187	-28,373	-24,559	-20,946	-17,941	-15,930	-13,456	-11,488	-8,961	-7,611
Additional Paid-In Capital	5.4%	68,670	65,129	62,447	62,119	59,137	58,847	53,106	52,817	52,530	41,604	41,260	40,754	35,777	34,870	20,399	19,639	19,315	19,073	8,948	7,049
Shares Outstanding	71.1%	10,635	6,215	4,207	4,141	2,226	1,617	1,321	1,314	1,294	949	915	848	845	-	-	-	-	-	-	-
Float	-	-	-	-	8,780	-	-	-	8,780	-	-	-	-	-	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-25.9%	-3,192	-2,536	-3,376	-3,402	-4,824	-2,305	-1,812	-3,362	-3,077	-3,236	-1,995	-4,997	-3,308	-1,446	-1,273	-2,742	-1,855	-2,475	-378	-616	-82.69
Share Based Compensation	-12.8%	203	233	195	290	290	290	290	287	337	317	507	470	431	363	365	323	242	190	173	70.00	44.00
Cashflow From Investing	100.0%	-	-2.16	-1.74	-	-	1*	-1.51	-2.91	-	-2.08	-	-	-3.67	-	-	-11.53	-6.41	-11.74	-	-8.38	-
Cashflow From Financing	58.8%	3,459	2,178	8.00	2,571	-120	5,333	-117	-116	10,513	-82.83	3,436	808	347	14,179	-45.00	-	-	8,829	97.00	1,382	-48.02

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CNSP Income Statement

2024-03-31

Statements of Operations (Unaudited) - USD ($)	3 Months Ended
Statements of Operations (Unaudited) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
General and administrative	$ 1,114,442	$ 1,358,752
Research and development	2,430,412	3,567,759
Total operating expenses	3,544,854	4,926,511
Loss from operations	(3,544,854)	(4,926,511)
Other income (expenses):
Interest income	6,731	0
Interest expense	(6,625)	(5,436)
Total other income (expense)	106	(5,436)
Net loss	$ (3,544,748)	$ (4,931,947)
Loss per share - basic	$ (0.41)	$ (2.59)
Loss per share - diluted	$ (0.41)	$ (2.59)
Weighted average shares outstanding - basic	8,712,680	1,906,494
Weighted average shares outstanding - diluted	8,712,680	1,906,494

CNSP Balance Sheet

2024-03-31

Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 815,226	$ 548,721
Deferred offering costs	0	202,859
Prepaid expenses and other current assets	786,050	839,590
Total current assets	1,601,276	1,591,170
Noncurrent Assets:
Prepaid expenses, net of current portion	55,296	104,750
Property and equipment, net	4,305	4,933
Total noncurrent assets	59,601	109,683
Total Assets	1,660,877	1,700,853
Current Liabilities:
Accounts payable and accrued expenses	5,878,298	5,832,162
Notes payable	213,104	300,806
Total current liabilities	6,091,402	6,132,968
Total Liabilities	6,091,402	6,132,968
Commitments and contingencies
Stockholders' Equity (Deficit):
Preferred stock, $0.001 par value, 5,000,000 shares authorized and 0 shares issued and outstanding	0	0
Common stock, $0.001 par value, 75,000,000 shares authorized and 10,668,932 and 6,214,598 shares issued and outstanding, respectively	10,669	6,214
Additional paid-in capital	68,670,457	65,128,574
Accumulated deficit	(73,111,651)	(69,566,903)
Total Stockholders' Equity (Deficit)	(4,430,525)	(4,432,115)
Total Liabilities and Stockholders' Equity (Deficit)	$ 1,660,877	$ 1,700,853

About CNS Pharmaceuticals Inc

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

CEO	Mr. John Michael Climaco Esq., J.D.
WEBSITE	cnspharma.com
INDUSTRY	Biotechnology
EMPLOYEES	3

CNS Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for CNS Pharmaceuticals Inc? What does CNSP stand for in stocks?

CNSP is the stock ticker symbol of CNS Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CNS Pharmaceuticals Inc (CNSP)?

As of Fri May 17 2024, market cap of CNS Pharmaceuticals Inc is 2.61 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CNSP stock?

You can check CNSP's fair value in chart for subscribers.

What is the fair value of CNSP stock?

You can check CNSP's fair value in chart for subscribers. The fair value of CNS Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of CNS Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CNSP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is CNS Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether CNSP is over valued or under valued. Whether CNS Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact CNS Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CNSP.

What is CNS Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CNSP's PE ratio (Price to Earnings) is -0.15 and Price to Sales (PS) ratio is 75.76. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CNSP PE ratio will change depending on the future growth rate expectations of investors.